Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Boston Scientific Corp. (BSX) Tuesday said it received U.S. Food and Drug Administration clearance of the EXALT Model B Single-Use Bronchoscope, designed for use in bedside procedures within the intensive care unit and operating room.


RTTNews | Aug 10, 2021 04:21PM EDT

16:20 Tuesday, August 10, 2021 (RTTNews.com) - Boston Scientific Corp. (BSX) Tuesday said it received U.S. Food and Drug Administration clearance of the EXALT Model B Single-Use Bronchoscope, designed for use in bedside procedures within the intensive care unit and operating room.

The EXALT Model B Bronchoscope can be used for a wide range of bronchoscopy procedures such as secretion management, airway intubation, percutaneous tracheostomy, double lumen endotracheal tube placement and biopsies.

"To effectively diagnose and treat disorders in the lungs and air passages, physicians require devices that provide high-quality imaging and visualization into a patient's anatomy," said Carla R. Lamb, MD, director, Interventional Pulmonary Medicine and director, Interventional Pulmonary Fellowship Program, Lahey Hospital & Medical Center. "In my view, this device represents a scientific advancement in single-use bronchoscopes which could improve patient care."

Throughout the United States, more than 1.2 million bedside procedures involving a bronchoscope are performed in ICU and OR settings each year, and more than 3 million are performed worldwide.

Read the original article on RTTNews ( https://www.rttnews.com/3217792/boston-scientific-gets-fda-clearance-for-exalt-model-b-single-use-bronchoscope.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC